Review Article
Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors
Table 3
Characteristics of certain HDACIs tested in CTCL.
| | | HDAC class specificity | Potency | Route of administration | Clinical Status | Structure |
| | Vorinostat | I, II, IV | nM | Oral | FDA approved (2006) | | Hydroxamate | Belinostat (PXD101) | I, II, IV | nM | Oral/intravenous | Phase I, II | | | Panobinostat (LBH589) | I, II, IV | nM | Oral | Phase II, III | |
| Benzamide | Entinostat (MS-275) | I | M | Oral | Phase II | |
| Cyclic tetrapeptide | Depsipeptide (FK228, romidepsin) | I, II, IV | nM | Intravenous | FDA approved (2009) | |
|
|